Summary
71.81 0.99(1.40%)07/10/2025
AstraZeneca PLC (AZN)
AZN reported last earnings on 2025-04-29 after the market. An EPS of $1.24 was observed compared to an estimated EPS of $1.1, resulting in a surprise value of $0.14. A revenue of $13,588 million was observed compared to an estimated revenue of $14,058 million, resulting in a surprise value of $-470 Million.
AstraZeneca PLC (AZN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 1.40 | 3.40 | -2.74 | 10.70 | 8.67 | -5.79 | 50.96 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Strong Buy |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Strong Sell |
| P/B | Strong Sell |
Earnings
| Trading Data | ||
| Close | 71.81 | |
| Open | 71.65 | |
| High | 72.46 | |
| Low | 71.29 | |
| Volume | 4,042,918 | |
| Change | 0.99 | |
| Change % | 1.40 | |
| Avg Volume (20 Days) | 4,129,782 | |
| Volume/Avg Volume (20 Days) Ratio | 0.98 | |
| 52 Week Range | 61.81 - 86.47 | |
| Price vs 52 Week High | -16.95% | |
| Price vs 52 Week Low | 16.18% | |
| Range | 0.00 | |
| Gap Up/Down | 0.78 | |
Profitibility | ||
| Market Capitalization (Mln) | 432,660 | |
| Revenue per share | 17.7361 | |
| Net Income per share | 2.5071 | |
| Dividend Yield | 0.0214 | |
| Dividend Share | 154.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 57.2854 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
07/10 09:47 EST - proactiveinvestors.co.uk
Trumps 200% tariffs. Here's what it means for UK pharma investors
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
Trumps 200% tariffs. Here's what it means for UK pharma investors
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
07/09 09:46 EST - proactiveinvestors.co.uk
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN)Â should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN)Â should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
07/08 11:46 EST - zacks.com
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
07/08 07:00 EST - seekingalpha.com
AstraZeneca: Just What The Doctor Ordered
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations, and key therapy areas like oncology and respiratory are driving...
AstraZeneca: Just What The Doctor Ordered
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations, and key therapy areas like oncology and respiratory are driving...
07/04 09:36 EST - zacks.com
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
07/04 05:10 EST - seekingalpha.com
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory...
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory...
07/04 03:15 EST - proactiveinvestors.co.uk
AstraZeneca wins EU approval for Imfinzi in early bladder cancer treatment
AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step forward in treatment options for the disease. The approval means Imfinzi is now the first and only...
AstraZeneca wins EU approval for Imfinzi in early bladder cancer treatment
AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step forward in treatment options for the disease. The approval means Imfinzi is now the first and only...
07/03 18:26 EST - fool.com
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
Why AstraZeneca Stock Got Thumped on Thursday
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
07/03 11:38 EST - youtube.com
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Report: Summit in talks for $15 billion partnership with AstraZeneca
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
07/02 10:47 EST - invezz.com
AstraZeneca exit: here's what it really means for the UK
AstraZeneca Plc (LON: AZN) is in focus this morning following reports that its chief executive – Pascal Soriot is considering moving the giant's listing to the US.
AstraZeneca exit: here's what it really means for the UK
AstraZeneca Plc (LON: AZN) is in focus this morning following reports that its chief executive – Pascal Soriot is considering moving the giant's listing to the US.
07/02 09:51 EST - zacks.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
07/02 09:02 EST - proactiveinvestors.co.uk
Are these the UK's top income stocks? One leading bank thinks so
Reliable income stocks are a staple of a balanced portfolio. But according to research from UBS, the UK has only a handful that warrant close attention.
Are these the UK's top income stocks? One leading bank thinks so
Reliable income stocks are a staple of a balanced portfolio. But according to research from UBS, the UK has only a handful that warrant close attention.
07/01 19:16 EST - zacks.com
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
Astrazeneca (AZN) reached $71.46 at the closing of the latest trading day, reflecting a +2.26% change compared to its last close.
Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
Astrazeneca (AZN) reached $71.46 at the closing of the latest trading day, reflecting a +2.26% change compared to its last close.
07/01 17:18 EST - fool.com
Why AstraZeneca Stock Topped the Market on Tuesday
Trading in AstraZeneca's (AZN 2.26%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session.
Why AstraZeneca Stock Topped the Market on Tuesday
Trading in AstraZeneca's (AZN 2.26%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session.
07/01 11:13 EST - proactiveinvestors.co.uk
AstraZeneca shares pop on news CEO wants to move base to US
AstraZeneca PLC (LSE:AZN) shares spiked higher on Tuesday afternoon on reports that the boss of the UK pharmaceutical giant wants to move the company to the US. CEO Pascal Soriot wants to the FTSE 100's largest company to leave the UK due to his frustration with restrictions on medicines and...
AstraZeneca shares pop on news CEO wants to move base to US
AstraZeneca PLC (LSE:AZN) shares spiked higher on Tuesday afternoon on reports that the boss of the UK pharmaceutical giant wants to move the company to the US. CEO Pascal Soriot wants to the FTSE 100's largest company to leave the UK due to his frustration with restrictions on medicines and...
07/01 09:37 EST - seekingalpha.com
AstraZeneca: Navigating Challenges Across Geographies Well
AstraZeneca's price performance YTD exceeds the healthcare sector and broader markets, indicating investors are assuaged regarding concerns across geographies. The company has offered greater clarity on why its under investigation in China, and so far there's reason to believe matters are under...
AstraZeneca: Navigating Challenges Across Geographies Well
AstraZeneca's price performance YTD exceeds the healthcare sector and broader markets, indicating investors are assuaged regarding concerns across geographies. The company has offered greater clarity on why its under investigation in China, and so far there's reason to believe matters are under...
07/01 08:26 EST - proactiveinvestors.co.uk
AstraZeneca's patent headwinds receding as trial data offers excitement
UBS has maintained its 'buy' recommendation on AstraZeneca PLC (LSE:AZN), setting a 12-month price target of 10,121p, reflecting confidence that a wave of late-stage clinical readouts will provide fresh share-price catalysts after a period dominated by patent expiries and pricing headwinds....
AstraZeneca's patent headwinds receding as trial data offers excitement
UBS has maintained its 'buy' recommendation on AstraZeneca PLC (LSE:AZN), setting a 12-month price target of 10,121p, reflecting confidence that a wave of late-stage clinical readouts will provide fresh share-price catalysts after a period dominated by patent expiries and pricing headwinds....
06/28 06:35 EST - fool.com
3 No-Brainer Stocks to Buy for Under $100 Right Now
What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.
3 No-Brainer Stocks to Buy for Under $100 Right Now
What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.